Lenvima plus Keytruda with TACE significantly improved progression-free survival in unresectable, non-metastatic hepatocellular carcinoma compared to TACE with placebo. The study reported a median ...

For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) improves ...

A meta-analysis found that patients with early and intermediate-stage hepatocellular carcinoma who received external beam radiation therapy (EBRT) demonstrated better local control and ...

SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular ...

Mortality and 30-day readmissions among hepatocellular carcinoma patients hospitalized for portal vein thrombosis: A nationwide analysis. This is an ASCO Meeting Abstract from the 2026 ASCO ...

Liver resection should be the primary therapeutic option for patients with early multinodular hepatocellular carcinoma (HCC) who are ineligible for transplant, a retrospective cohort study suggested.

The efficacy of transarterial techniques can be assessed in terms of imaging response (CT scan), biologic response (AFP), degree of tumor necrosis, patient survival or quality of life. The most ...

Patients with very early or early-stage hepatocellular carcinoma have similar survival with external beam radiation as they ...

There are no contraindications for IMFINZI® (durvalumab) or IMJUDO® (tremelimumab-actl). Severe and Fatal Immune-Mediated Adverse Reactions Important immune-mediated adverse reactions listed under ...